Emerging pharmacotherapy for the treatment of cannabis use disorder

References

• SAMHSA. Key substance use and mental health indicators in the United States: results from the 2020. National survey on drug use and health (HHS publication No. PEP21-07-01-003, NSDUH series H-56). Center for behavioral health statistics and quality, substance abuse and …. 2021.
   Google Scholar
• Leung J, Chan GCK, Hides L, et al. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Add Behav. 2020 Oct 01;109:106479. doi: 10.1016/j.addbeh.2020.106479
   PubMed Web of Science ®Google Scholar
• Forti M, Quattrone D, Freeman T, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019 Mar 01;6(5):427–436. doi: 10.1016/S2215-0366(19)30048-3
   PubMed Web of Science ®Google Scholar
• Shamabadi A, Ahmadzade A, Pirahesh K, et al. Suicidality risk after using cannabis and cannabinoids: an umbrella review. Dialogues Clin Neurosci. 2023 Dec;25(1):50–63. doi: 10.1080/19585969.2023.2231466
   PubMed Web of Science ®Google Scholar
• Hasin DS, Kerridge BT, Saha TD, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the national epidemiologic survey on alcohol and related conditions-III. Am J Psychiatry. 2016 Jun 1;173(6):588–599. doi: 10.1176/appi.ajp.2015.15070907
   PubMed Web of Science ®Google Scholar
• Shao H, Du H, Gan Q, et al. Trends of the Global Burden of disease attributable to cannabis use disorder in 204 countries and territories, 1990-2019: results from the disease Burden study 2019. Int J Ment Health Addict. 2023 Feb;10:1–23. doi: 10.1007/s11469-022-00999-4
   Google Scholar
• Gryczynski J, Schwartz RP, O’Grady KE, et al. Understanding patterns of high-cost health care use across different substance user groups. Health Aff. 2016 Jan;35(1):12–19. doi: 10.1377/hlthaff.2015.0618
   Web of Science ®Google Scholar
• UNOoDa C. World Drug Report 2019 (united nations publication, sales No. E. 19. X. 8). Report. 2019.
   Google Scholar
• Squeglia LM, Fadus MC, McClure EA, et al. Pharmacological treatment of youth substance use disorders. J Child Adolesc Psychopharmacol. 2019 Aug;29(7):559–572. doi: 10.1089/cap.2019.0009
   PubMed Web of Science ®Google Scholar
• Compton WM, Pringle B. Services research on adolescent drug treatment. Commentary on “the cannabis youth treatment (CYT) study: main findings from two randomized trials”. J Subst Abuse Treat. 2004;27(3):195–196. doi: 10.1016/j.jsat.2004.07.003
   PubMed Web of Science ®Google Scholar
• Kadden RM, Litt MD, Kabela-Cormier E, et al. Abstinence rates following behavioral treatments for marijuana dependence. Add Behav. 2007;32(6):1220–1236. doi: 10.1016/j.addbeh.2006.08.009
   PubMed Web of Science ®Google Scholar
• Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict. 2007;16(5):331–342. doi: 10.1080/10550490701525665
   PubMed Web of Science ®Google Scholar
• Sherman BJ, McRae‐Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacother J Human Pharmacol Drug Ther. 2016;36(5):511–535. doi: 10.1002/phar.1747
   Google Scholar
• Bahji A, Meyyappan AC, Hawken ER, et al. Pharmacotherapies for cannabis use disorder: a systematic review and network meta-analysis. Int J Drug Policy. 2021 Nov;97:103295. doi: 10.1016/j.drugpo.2021.103295.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Pavlicova M, Choi CJ, et al. Quetiapine treatment for cannabis use disorder. Drug Alcohol Dependence. 2021;218:108366. doi: 10.1016/j.drugalcdep.2020.108366
   PubMed Web of Science ®Google Scholar
• Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019 Mar 26;4(1):5. doi: 10.1186/s41073-019-0064-8
   PubMedGoogle Scholar
• Paronis CA, Nikas SP, Shukla VG, et al. Δ(9)-tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol. 2012 Dec;23(8):802–805. doi: 10.1097/FBP.0b013e32835a7c4d
   PubMed Web of Science ®Google Scholar
• Vuilleumier C, Scherbaum N, Bonnet U, et al. Cannabinoids in the treatment of cannabis use disorder: systematic review of randomized controlled trials [Systematic Review]. Front Psychiatry. 2022 Jun 22;13:13. doi: 10.3389/fpsyt.2022.867878
   Google Scholar
• Augustin SM, Lovinger DM. Synaptic changes induced by cannabinoid drugs and cannabis use disorder. Neurobiol Dis. 2022 Jun 01;167:105670. doi: 10.1016/j.nbd.2022.105670
   PubMed Web of Science ®Google Scholar
• Connor JP, Stjepanović D, Le Foll B, et al. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7(1):16. doi: 10.1038/s41572-021-00247-4
   PubMed Web of Science ®Google Scholar
• Ferland J-M, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. Nat Neurosci. 2020 May 01;23(5):600–610. doi: 10.1038/s41593-020-0611-0.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Sabioni P, Gowing L, et al. Pharmacotherapies for cannabis use disorders: clinical challenges and promising therapeutic agents. Handb Exp Pharmacol. 2020;258:355–372.
   PubMedGoogle Scholar
• Valverde O, Maldonado R, Valjent E, et al. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci. 2000 Dec 15;20(24):9284–9289. doi: 10.1523/JNEUROSCI.20-24-09284.2000
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Sheikh SM, Loh HH, et al. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther. 2001 Sep;298(3):1007–1014.
   PubMed Web of Science ®Google Scholar
• Solinas M, Zangen A, Thiriet N, et al. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. Eur J Neurosci. 2004 Jun;19(12):3183–3192. doi: 10.1111/j.0953-816X.2004.03420.x
   PubMed Web of Science ®Google Scholar
• Mason BL, Mustafa A, Filbey F, et al. Novel pharmacotherapeutic interventions for cannabis use disorder. Curr Addict Rep. 2016;3(2):214–220. doi: 10.1007/s40429-016-0094-y
   Google Scholar
• Trigo JM, Soliman A, Quilty LC, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS One. 2018;13(1):e0190768. doi: 10.1371/journal.pone.0190768
   PubMed Web of Science ®Google Scholar
• Mills L, Dunlop A, Montebello M, et al. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Subst Abuse Treat Prev Policy. 2022 Oct 8;17(1):67. doi: 10.1186/s13011-022-00493-z
   PubMed Web of Science ®Google Scholar
• Freeman TP, Hindocha C, Baio G, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive bayesian trial. Lancet Psychiatry. 2020 Oct;7(10):865–874. doi: 10.1016/S2215-0366(20)30290-X
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Cortes-Briones J, Creatura G, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019 Jan;6(1):35–45. doi: 10.1016/S2215-0366(18)30427-9
   PubMed Web of Science ®Google Scholar
• Miranda R Jr., Treloar H, Blanchard A, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addict Biol. 2017 May;22(3):779–790. doi: 10.1111/adb.12350
   PubMed Web of Science ®Google Scholar
• Haney M, Ramesh D, Glass A, et al. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology. 2015 Oct;40(11):2489–2498. doi: 10.1038/npp.2015.108
   PubMed Web of Science ®Google Scholar
• Sugarman DE, De Aquino JP, Poling J, et al. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacol Biochem Behav. 2019 Jun;181:86–92. doi: 10.1016/j.pbb.2019.05.004
   PubMed Web of Science ®Google Scholar
• Prisciandaro JJ, Mellick W, Squeglia LM, et al. Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. Addict Biol. 2022 Jan;27(1):e13085. doi: 10.1111/adb.13085
   PubMed Web of Science ®Google Scholar
• Herrmann ES, Cooper ZD, Bedi G, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacol (Berl). 2016 Jul;233(13):2469–2478. doi: 10.1007/s00213-016-4298-6
   PubMed Web of Science ®Google Scholar
• McRae-Clark AL, Gray KM, Baker NL, et al. Varenicline as a treatment for cannabis use disorder: a placebo-controlled pilot trial. Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109111. doi: 10.1016/j.drugalcdep.2021.109111
   PubMedGoogle Scholar
• Allsop DJ, Lintzeris N, Copeland J, et al. Cannabinoid replacement therapy (CRT): nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther. 2015 Jun;97(6):571–574. doi: 10.1002/cpt.109
   PubMed Web of Science ®Google Scholar
• Trigo JM, Lagzdins D, Rehm J, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 2016 Apr 1;161:298–306. doi: 10.1016/j.drugalcdep.2016.02.020
   PubMed Web of Science ®Google Scholar
• Wang R, Trigo JM, Le Foll B. Effects of sub-chronic nabiximols on biological markers of individuals undergoing a clinical trial for the treatment of cannabis use disorder. Am J Transl Res. 2023;15(8):5228–5238.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018 May 17;378(20):1888–1897. doi: 10.1056/NEJMoa1714631
   PubMed Web of Science ®Google Scholar
• Silva GD, Del Guerra FB, de Oliveira Lelis M, et al. Cannabidiol in the treatment of epilepsy: a focused review of evidence and gaps. Front Neurol. 2020;11:531939. doi: 10.3389/fneur.2020.531939
   PubMed Web of Science ®Google Scholar
• Linge R, Jiménez-Sánchez L, Campa L, et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology. 2016 Apr;103:16–26. doi: 10.1016/j.neuropharm.2015.12.017
   PubMed Web of Science ®Google Scholar
• Chye Y, Christensen E, Solowij N, et al. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry. 2019;10:63. doi: 10.3389/fpsyt.2019.00063
   PubMed Web of Science ®Google Scholar
• Navarrete F, García-Gutiérrez MS, Gasparyan A, et al. Role of Cannabidiol in the therapeutic intervention for substance use disorders [review]. Front Pharmacol. 2021 May 20;12:12. doi: 10.3389/fphar.2021.626010
   Web of Science ®Google Scholar
• Cleirec G, Desmier E, Lacatus C, et al. Efficiency of inhaled cannabidiol in cannabis use disorder: the Pilot study Cannavap. Front Psychiatry. 2022;13:899221. doi: 10.3389/fpsyt.2022.899221
   PubMed Web of Science ®Google Scholar
• Fortin D, Di Beo V, Massin S, et al. A “good” smoke? The off-label use of cannabidiol to reduce cannabis use. Front Psychiatry. 2022;13:829944. doi: 10.3389/fpsyt.2022.829944
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63(Suppl 13):5–11.
   PubMed Web of Science ®Google Scholar
• Brezing CA, Levin FR. The Current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology. 2018 Jan;43(1):173–194. doi: 10.1038/npp.2017.212
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003 May 17;361(9370):1677–1685. doi: 10.1016/S0140-6736(03)13370-3
   PubMed Web of Science ®Google Scholar
• Oncken C, Arias AJ, Feinn R, et al. Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res. 2014 Mar;16(3):288–296. doi: 10.1093/ntr/ntt141
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013 Dec;70(12):1338–1346. doi: 10.1001/jamapsychiatry.2013.2295
   PubMed Web of Science ®Google Scholar
• Mason BL, Mustafa A, Filbey F, et al. Novel pharmacotherapeutic interventions for cannabis use disorder. Curr Addict Rep. 2016 Jun 01;3(2):214–220. doi: 10.1007/s40429-016-0094-y
   Google Scholar
• Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer’s disease. Int Psychogeriatr. 2002;14(Suppl 1):93–126. doi: 10.1017/S1041610203008688
   PubMedGoogle Scholar
• Jensen KP, DeVito EE, Yip S, et al. The cholinergic system as a treatment target for opioid use disorder. CNS Drugs. 2018 Nov;32(11):981–996. doi: 10.1007/s40263-018-0572-y
   PubMed Web of Science ®Google Scholar
• Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006 Feb;6(1):108–113. doi: 10.1016/j.coph.2005.11.003
   PubMed Web of Science ®Google Scholar
• Haney M, Cooper ZD, Bedi G, et al. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013 Jul;38(8):1557–1565. doi: 10.1038/npp.2013.54
   PubMed Web of Science ®Google Scholar
• Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 Sep;70(3):801–805. doi: 10.1124/mol.106.025130
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008 Aug;63(8):717–724. doi: 10.1136/thx.2007.090647
   PubMed Web of Science ®Google Scholar
• Hengartner MP, Plöderl M. Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work: effect size and method bias Matter! Front Psychiatry. 2018;9:517. doi: 10.3389/fpsyt.2018.00517
   PubMed Web of Science ®Google Scholar
• Kostis JB, Dobrzynski JM. Limitations of randomized clinical trials. Am J Cardiol. 2020;129:109–115.
   PubMed Web of Science ®Google Scholar
• Ebrahim Valojerdi A, Tanha K, Janani L. Important considerations in calculating and reporting of sample size in randomized controlled trials. Med J Islam Repub Iran. 2017;31(1):843–846. doi: 10.14196/mjiri.31.127
   Google Scholar
• Llewellyn-Bennett R, Bowman L, Bulbulia R. Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol. Syst Rev. 2016 Dec 15;5(1):214. doi: 10.1186/s13643-016-0393-3
   PubMedGoogle Scholar
• Capps B, Carter A, van der Eijk Y. Ethical issues in the treatment of addiction. In: Clausen J Levy N, editors. Handbook of neuroethics. Dordrecht: Springer Netherlands; 2015. p. 1045–1063.
   Google Scholar
• Rastegar DA, Fingerhood MI. 517Ethical and legal considerations. In: The American Society of Addiction Medicine Handbook of Addiction Medicine [internet]. Oxford University Press. 2015 [cited 2024 Jun 4]. Available from: 10.1093/med/9780190214647.003.0017
   Google Scholar
• Akhondzadeh S. Repositioning drugs for psychiatry. Avicenna J Med Biotechnol. 2020 Apr;12(2):67.
   PubMedGoogle Scholar
• Sofuoglu M, Sugarman DE, Carroll KM. Cognitive function as an emerging treatment target for marijuana addiction. Exp Clin Psychopharmacol. 2010 Apr;18(2):109–119. doi: 10.1037/a0019295
   PubMed Web of Science ®Google Scholar